OneCureGen Co., Ltd. is providing investment and patent/commercialization support by SYP.

iCure subsidiary OneCureGen (CEO Choi Young-kwon) announced on the 26th that the research results of peptide anticancer drugs currently being developed have been adopted as the American Cancer Research Society (AACR) 2024 'Late-Breaking Abstract'.

AACR is the world's largest cancer research conference, and various anticancer pipelines that major domestic and foreign bio companies are working on will be announced. It will be held from April 5 to April 10 at the San Diego Convention Center in California this year.

"In this AACR, OneCureGen announced two abstracts related to the development of VGLL1-derived peptide anticancer drugs, and one of them was selected as the latest innovation abstract," a company official said. "AACR adopts the latest innovation abstract containing notable innovative research content or important clinical trial results that have not been reported."

According to the company, the VGLL1-derived peptide (SCVP), which is the original technology of OneCureGen, has the effect of inhibiting cell proliferation of gastric cancer, breast cancer, pancreatic cancer, and ovarian cancer, and is being developed as a target treatment for advanced and triple-negative breast cancer. The company is working on discovering biomarkers for patient selection and developing combination therapy for SCVP treatment through experimental research on gene scissors.

A previous official said, "The biomarker-based SCVP anticancer drug technology, which shows the superiority of SCVP efficacy and the potential to treat intractable cancers that have been difficult to treat with existing anticancer drugs, is considered remarkable."